Literature DB >> 22205272

Autoimmune hepatitis induced by adalimumab with successful switch to abatacept.

A Grasland, R Sterpu, S Boussoukaya, I Mahe.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22205272     DOI： 10.1007/s00228-011-1191-4

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  20 in total

1.  Infliximab-induced autoimmune hepatitis in Crohn's disease treated with budesonide and mycophenolate.

Authors:  K Subramaniam; S Chitturi; M Brown; P Pavli
Journal:  Inflamm Bowel Dis       Date:  2011-08-30       Impact factor: 5.325

2.  Autoimmune hepatitis in two psoriasis patients treated with inflixmab.

Authors:  Catherine Goujon; Karima Dahel; Frédéric Bérard; Isabelle Guillot; Nathalie Gunera-Saad; Jean-François Nicolas
Journal:  J Am Acad Dermatol       Date:  2010-08       Impact factor: 11.527

3.  Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis.

Authors:  V Germano; A Picchianti Diamanti; G Baccano; E Natale; A Onetti Muda; R Priori; G Valesini
Journal:  Ann Rheum Dis       Date:  2005-10       Impact factor: 19.103

4.  Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis.

Authors:  Gerard Ozorio; Bruce McGarity; Haesung Bak; Andrew S Jordan; Henry Lau; Cathy Marshall
Journal:  Med J Aust       Date:  2007-11-05       Impact factor: 7.738

5.  Autoimmune hepatitis associated with infliximab in a patient with palmoplantar pustular psoriaisis.

Authors:  D A Fairhurst; R Sheehan-Dare
Journal:  Clin Exp Dermatol       Date:  2009-04       Impact factor: 3.470

6.  Development of autoimmune hepatitis in a child with systemic-onset juvenile idiopathic arthritis during therapy with etanercept.

Authors:  Basil M Fathalla; Donald P Goldsmith; Judy Mae C Pascasio; Alan Baldridge
Journal:  J Clin Rheumatol       Date:  2008-10       Impact factor: 3.517

7.  Etanercept tolerance in a patient with previous infliximab-induced hepatitis.

Authors:  Heidemarie Becker; Peter Willeke; Wolfram Domschke; Markus Gaubitz
Journal:  Clin Rheumatol       Date:  2008-09-16       Impact factor: 2.980

8.  Infliximab-induced autoimmune hepatitis with successful switch to adalimumab in a patient with Crohn's disease: the index case.

Authors:  Dahlia A Goldfeld; Elizabeth C Verna; Jay Lefkowitch; Arun Swaminath
Journal:  Dig Dis Sci       Date:  2011-05-20       Impact factor: 3.199

9.  International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.

Authors:  F Alvarez; P A Berg; F B Bianchi; L Bianchi; A K Burroughs; E L Cancado; R W Chapman; W G Cooksley; A J Czaja; V J Desmet; P T Donaldson; A L Eddleston; L Fainboim; J Heathcote; J C Homberg; J H Hoofnagle; S Kakumu; E L Krawitt; I R Mackay; R N MacSween; W C Maddrey; M P Manns; I G McFarlane; K H Meyer zum Büschenfelde; M Zeniya
Journal:  J Hepatol       Date:  1999-11       Impact factor: 25.083

10.  Autoimmune hepatitis induced by infliximab in a patient with Crohn's disease with no relapse after switching to adalimumab.

Authors:  Marilia Cravo; Rosa Silva; Miguel Serrano
Journal:  BioDrugs       Date:  2010-12-14       Impact factor: 5.807
View more
  13 in total

Review 1.  Hepatotoxicity Associated with the Use of Anti-TNF-α Agents.

Authors:  Joshua B French; Maurizio Bonacini; Marwan Ghabril; David Foureau; Herbert L Bonkovsky
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

2.  Severe cholestasis due to adalimumab in a Crohn's disease patient.

Authors:  Edward Kim; Brian Bressler; David F Schaeffer; Eric M Yoshida
Journal:  World J Hepatol       Date:  2013-10-27

Review 3.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

Review 4.  Current concepts in the diagnosis and management of autoimmune hepatitis.

Authors:  Stephen Kriese; Michael A Heneghan
Journal:  Frontline Gastroenterol       Date:  2012-11-12

Review 5.  Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics.

Authors:  Nikolaos K Gatselis; Kalliopi Zachou; George K Koukoulis; George N Dalekos
Journal:  World J Gastroenterol       Date:  2015-01-07       Impact factor: 5.742

Review 6.  Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases.

Authors:  Marwan Ghabril; Herbert L Bonkovsky; Clarissa Kum; Tim Davern; Paul H Hayashi; David E Kleiner; Jose Serrano; Jim Rochon; Robert J Fontana; Maurizio Bonacini
Journal:  Clin Gastroenterol Hepatol       Date:  2013-01-17       Impact factor: 11.382

Review 7.  Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Authors:  Robert Hirten; Keith Sultan; Ashby Thomas; David E Bernstein
Journal:  World J Hepatol       Date:  2015-11-28

8.  Autoimmune Hepatitis Triggered by Anti-TNF-α Therapy.

Authors:  Satoshi Nakayama
Journal:  Case Rep Med       Date:  2013-09-08

9.  Cholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments.

Authors:  Joerg Latus; Reinhild Klein; Ina Koetter; Matthias Schwab; Peter Fritz; Martin Kimmel; M Dominik Alscher; Niko Braun
Journal:  PLoS One       Date:  2013-11-11       Impact factor: 3.240

Review 10.  Challenges and approaches for the development of safer immunomodulatory biologics.

Authors:  Jean G Sathish; Swaminathan Sethu; Marie-Christine Bielsky; Lolke de Haan; Neil S French; Karthik Govindappa; James Green; Christopher E M Griffiths; Stephen Holgate; David Jones; Ian Kimber; Jonathan Moggs; Dean J Naisbitt; Munir Pirmohamed; Gabriele Reichmann; Jennifer Sims; Meena Subramanyam; Marque D Todd; Jan Willem Van Der Laan; Richard J Weaver; B Kevin Park
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 112.288
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.